Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR-709
- Development stage
- Discontinued
- Lead developer
- Lallemand
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AR-709 is an experimental, synthetic, low-molecular-weight diaminopyrimidine antibiotic originally developed by Arpida AG. It functions as a bacterial dihydrofolate reductase (DHFR) inhibitor, which disrupts the synthesis of bacterial DNA, RNA, and proteins. The drug was specifically designed to target respiratory tract infections, demonstrating potent in vitro activity against *Streptococcus pneumoniae*, including multidrug-resistant and trimethoprim-sulfamethoxazole-resistant strains. Clinical development reached phase 0 microdose studies to evaluate its pharmacokinetic profile and penetration into lung compartments, but further development appears to have stalled following Arpida's financial difficulties and the failure of its lead candidate, iclaprim.
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on AR-709.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR-709.